RevMed

RevMed received FDA approval for Rasonque, a pancreatic cancer drug using a novel 'molecular glue' approach to target RAS mutations. In late-stage trials, the drug helped patients survive to 13 months versus shorter survival with chemotherapy alone. Analysts forecast potential annual sales exceeding $20 billion.